Last reviewed · How we verify
Emetogenic chemotherapy
Emetogenic chemotherapy is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving emetogenic chemotherapy.
Emetogenic chemotherapy refers to chemotherapy agents that induce nausea and vomiting as a side effect, rather than a drug with a specific anti-emetic mechanism.
Emetogenic chemotherapy refers to chemotherapy agents that induce nausea and vomiting as a side effect, rather than a drug with a specific anti-emetic mechanism. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving emetogenic chemotherapy.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway. -
Big-pharma sponsor
+3.0pp
Merck Sharp & Dohme LLC is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Emetogenic chemotherapy |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Emetogenic chemotherapy is a classification of cytotoxic chemotherapy drugs (such as cisplatin, doxorubicin, and cyclophosphamide) that trigger chemotherapy-induced nausea and vomiting (CINV) through activation of chemoreceptor trigger zones and vagal afferent pathways. This is not a drug itself but rather a category describing the emetogenic potential of various chemotherapy agents used in cancer treatment.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving emetogenic chemotherapy
Common side effects
- Nausea
- Vomiting
- Retching
Key clinical trials
- An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC (PHASE4)
- Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (PHASE3)
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (PHASE2, PHASE3)
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (PHASE3)
- A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC (PHASE3)
- Pancreatic Adenocarcinoma Signature Stratification for Treatment (PHASE2)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Emetogenic chemotherapy CI brief — competitive landscape report
- Emetogenic chemotherapy updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Emetogenic chemotherapy
What is Emetogenic chemotherapy?
How does Emetogenic chemotherapy work?
What is Emetogenic chemotherapy used for?
Who makes Emetogenic chemotherapy?
What development phase is Emetogenic chemotherapy in?
What are the side effects of Emetogenic chemotherapy?
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving emetogenic chemotherapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing